Mark McClellan, Duke-Margolis Center for Health Policy

Duke to host pri­vate meet­ing with pay­ers and bio­phar­ma on how to pay for Alzheimer's drugs

How is the US go­ing to re­strict the use of Bio­gen’s new Alzheimer’s drug so Medicare doesn’t go bank­rupt be­fore the end of the decade? That’s the mul­ti-bil­lion dol­lar ques­tion that the fed­er­al gov­ern­ment, pay­ers, and clin­i­cians will need to hash out as the more than 6 mil­lion peo­ple with Alzheimer’s turn to Aduhelm as a po­ten­tial op­tion.

But with scant de­tails on how those cov­er­age de­ter­mi­na­tions will be made, it’s un­clear how ex­act­ly the Cen­ters for Medicare and Med­ic­aid Ser­vices will pay for Aduhelm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.